• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Nycomed, Neurochem gang up on Alzheimer’s

Article

Nycomed and Neurochem have struck an alliance aimed at developing novel technologies for the diagnosis of Alzheimer’s disease. Using Neurochem’s proprietary molecules as a basis, the two companies will work on the design and selection of a

Nycomed and Neurochem have struck an alliance aimed at developing novel technologies for the diagnosis of Alzheimer’s disease. Using Neurochem’s proprietary molecules as a basis, the two companies will work on the design and selection of a product to detect the presence of amyloid plaques that accumulate in the brains of Alzheimer’s patients.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.